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Abstract
Introduction: The nature of post-sarcoidosis fatigue syndrome (PSFS) is unknown and tools for the assessment of health quality 
(HQ) in these patients have not been fully assessed. The aim was to validate the Polish version of sarcoidosis health questionnaire 
(SHQ) and verify the association of HQ with fatigue and depressive symptoms among Polish patients with PSFS.
Material and methods: 71 patients with sarcoidosis (34 women, the mean age 47) were divided to: PSFS (n = 21), active 
sarcoidosis (S-A, n = 27) and sarcoidosis with complete remission (S-R, n = 23) groups. Fatigue Assessment Scale (FAS) was 
used to define significant fatigue (≥ 22 points). Polish version of SHQ was prepared by the authors and validated. Beck Depression 
Index (BDI) and Patient Health Questionnaire 9 (PHQ-9) were used to evaluate self-reported depressive symptoms.
Results: Polish version of SHQ was proved reliable and valid. HQ was worse and depressive symptoms were more frequent in 
PSFS and S-A when compared with S-R group. SHQ total score correlated negatively with depressive symptoms (r = –0.787 for 
BDI and r = –0,755 for PHQ-9, p < 0.01). A negative correlation between SHQ and FAS score was found (r = –0.784, p < 0.01). 
FAS score correlated with depressive symptoms (r = 0.726 for BDI and r = 0.755 for PHQ-9, p < 0.01).
Conclusion: Polish version of SHQ is a valuable tool for the assessment of HQ in sarcoidosis. HQ is impaired in PSFS comparing 
to patients with complete remission, but is comparable to active sarcoidosis. Depressive symptoms impact HQ and may influence 
perception of fatigue. Both fatigue and depression have a negative impact on HQ in sarcoidosis. 
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Introduction
Sarcoidosis is a chronic inflammatory dise-
ase of unknown etiology, which mainly affects 
intrathoracic lymph nodes and lung parenchyma, 
with possible involvement of other organs. Non-
caseating granulomas consisting of epithelioid 
and giant cells are found in histopathological 
examination of tissue samples taken from com-
promised organs [1, 2]. The overall prognosis is 
good, as about 60% of patients, regardless clinical 
phenotype, experience spontaneous remissions. 
Deaths — mainly due to lung fibrosis, heart 
involvement or neurosarcoidosis — are rare [1, 2]. 
The clinical presentation is variable. Symptom-
less course with accidental diagnosis is frequent. 
Many patients present symptoms resulting from 
specific organ involvement or from other disease-
-related pathological processes, like impairment 
of calcium metabolism. Many general symptoms 
are non-specific, for example weight loss, elevated 
temperature, sweats, myalgia or arthralgia [1–3]. 
Fatigue is one of the most frequently reported 
symptoms in active sarcoidosis (50–70% of pa-
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tients according to different sources), and is frequ-
ently associated with other general symptoms, for 
instance myalgia, arthralgia, night sweats [2–4]. It 
severely impacts quality of life [4] and is difficult 
to treat [5, 6]. 
Patients with diversity of acute and chronic 
diseases frequently report fatigue. Chronic fatigue 
is reported by patients infected with Ebstein-Bar 
(EBV), human immunodeficiency (HIV), hepatitis C 
(HCV) viruses, patients with neoplastic disease, 
rheumatoid arthritis and systemic sclerosis, mul-
tiple sclerosis, fibromyalgia, obstructive sleep ap-
nea and many others [7, 8]. American Centers for 
Disease Control and Prevention (CDC) proposed 
a term chronic fatigue syndrome (CFS), defined 
as a “debilitating and complex disorder characte-
rized by intense fatigue that is not improved by 
bed rest and that may be worsened by physical 
activity or mental exertion” [7]. 
In view of the above, chronic fatigue in the 
course of active sarcoidosis is not an unexpected 
symptom. However, it is especially intriguing, 
that it may appear and persist for a long period 
of time in patients with radiological and clinical 
remission. Sharma used a term post-sarcoidosis 
fatigue syndrome (PSFS) and estimated its frequ-
ency to about 5% [9]. The origin of fatigue in sar-
coidosis is still unknown. In active disease several 
factors should be considered, for instance syste-
mic inflammation, muscle involvement, extra-
pulmonary locations, comorbidities, pulmonary 
hypertension, impaired lung function, steroids 
and other drugs used for the treatment of sarco-
idosis, and psychological factors [10]. The path-
ogenesis of PSFS is even more mysterious [11, 12]. 
Depression and anxiety is frequent in patients 
with active sarcoidosis [12–14]. There are few 
reports pointing out the possible link between 
fatigue with depression. Goracci et al. [15] 
reported on strong relationship between sarcoido-
sis and its negative impact on quality of life. De 
Klejn et al. [16] found, that fatigue is related to 
depression in 34−36% and to anxiety in 43−46% 
of patients suffering from active sarcoidosis. The 
problem of underlying depression and its influ-
ence on fatigue has not been, however, studied in 
patients with sarcoidosis remission. In addition 
to that, fatigue is difficult to quantify objectively, 
and different measures have been applied for its 
assessment so far. Fatigue Assessment Scale is 
a self-administered questionnaire quantified and 
validated in the assessment of fatigue in different 
diseases, including sarcoidosis [17]. 
Assessment of health-related quality of life 
may be as important as assessment of depressive 
symptoms and fatigue among patients suffering 
from sarcoidosis [15]. Sarcoidosis Health Qu-
estionnaire (SHQ) is one of the most popular 
psychometric tools assessing quality of life desi-
gned for patients with sarcoidosis [18]. The SHQ 
questionnaire, as well as other questionnaires 
used for the assessment of accompanying fatigue 
and depression have not been used in patients 
with PSFS. Also, no validation of Polish version 
of SHQ has been published up to date.
Therefore, the aim of this study was to va-
lidate the Polish version of SHQ and verify the 
association of quality of life with fatigue and 
depressive symptoms among patients with PSFS.
Material and methods
Participants 
The study included 71 patients with sarcoido-
sis (34 women and 37 men) aged 28–80 years (the 
mean age 46,82 years), who reported to Outpatient 
Clinic and to Department of Pneumology and Al-
lergy of the First Clinical University Hospital in 
Lodz. Sarcoidosis was diagnosed in accordance 
with the criteria of the American Thoracic Society 
and World Association for Sarcoidosis and Other 
Granulomatous Disorders (ATS/WASOG) [19]. The 
study group was divided in three cohorts:
1)  Group A, consisting of 21 patients with clini-
cal and radiological remission and symptoms 
of fatigue, representing post-sarcoidosis fa-
tigue syndrome (PSFS) group. These patients 
had normal chest x-ray, showing complete 
remission of previous radiological changes. 
In doubtful cases chest high resolution com-
puted tomography (HRCT) was performed 
to confirm complete radiological resolution. 
None of the patients from this group had 
signs of extrapulmonary organs involvement 
or abnormal laboratory tests results. Fatigue 
assessment scale (FAS) was used to define 
patients with significant fatigue, and the 
score of ≥ 22 was used as a threshold [17].
2)  Group B, consisting of 23 patients with clinical 
remission without fatigue, representing a group 
of complete remission (SR). These patients had 
normal chest x-ray, showing complete remis-
sion of previous radiological changes, had no 
signs of extrapulmonary organs involvement, 
normal laboratory tests results, and no symp-
toms. The lack of significant fatigue symptoms 
was defined by the FAS score ≤ 21 [17];
3)  Group C, consisting of 27 patients with active 
sarcoidosis (AS). For the purpose of this study 
the disease was considered active, when the 
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patient presented with new-onset radiological 
changes or radiological progression, reported 
acute symptoms (fever, arthritis, erythema 
nodosum), or respiratory symptoms (cough, 
dyspnea, chest tightness) in the presence 
of typical radiological picture, when other 
causes of these symptoms were excluded. In 
patients with BAL performed in the previous 
3 months, increased % of lymphocytes above 
20% was considered abnormal, and spoke for 
activity. 11 patients from this group presented 
symptoms of Löfgren syndrome.
None of the patients smoked cigarettes. None 
of the patients in the study had been treated with 
oral corticosteroids or immunosuppressive drugs. 
No symptoms of chronic concomitant diseases 
which could provoke and increase fatigue or 
contribute to patient mental health were reported. 
Also no symptoms of acute infection were ob-
served in the patients during and prior to the stu-
dy. None of the women participating in the study 
was pregnant at the time of the study. There were 
no patients with extrapulmonary sarcoidosis. We 
followed the recruitment protocol according to 
which, patients with radiological and clinical 
remission were screened for chronic fatigue with 
FAS questionnaire first, and after completing the 
desired number of patients in each group (S-R and 
PSFS), the third group of patients with active sar-
coidosis was selected from patients consecutively 
presenting at the centre, with regard of inclusion/ 
/exclusion criteria written above. Estimation of 
the frequency of chronic fatigue or PSFS in the 
entire population of sarcoidosis patients was not 
the aim of our study. 
 In all the participants spirometry (Lungtest 
1000, MES, Poland) and diffusing capacity for car-
bon monoxide study (DLco) (MES, Poland) were 
performed in accordance with the ATS/ERS and 
Polish guidelines [20, 21]. The obtained results 
of forced vital capacity (FVC), forced expiratory 
volume in 1 second (FEV1), and DLco (corrected 
for hemoglobin concentration — DLCOc) were 
expressed as a percentage of predicted values. 
Chest x-ray was performed in all patients. 
In patients with active sarcoidosis the Scadding 
classification [1] was used to define radiological 
stage (stage 1 — enlarged hilar lymph nodes; stage 
2 — enlarged hilar lymph nodes with parenchy-
mal changes; stage 3 — parenchymal changes 
without enlarged hilar lymph nodes). 
Questionnaires
The Polish version of the Sarcoidosis Health 
Questionnaire was devised by means of a standard 
psychometric procedure, i.e. the forward-back-
ward translation [22]. Two pulmonologists trans-
lated the SHQ independently and consulted on 
the final content, which was counter-translat-
ed and compared with the original SHQ. The 
questionnaire comprises 29 items divided into 
three domain: Daily Functioning (DF, 13 items), 
Physical Functioning (PF, 6 items) and Emotional 
Functioning (EF, 10 items). Each item is scored 
on a 7-point Likert scale. Total score and scores 
in each domain are sums of the scores divided 
by the number of items. Higher scores in SHQ 
reflect better health-related quality of life among 
patients with sarcoidosis. 
The Beck Depression Index (BDI) was used 
to evaluate self-reported depressive symptoms 
[23, 24]. The Polish adaptation was developed 
by Zawadzki et al. [25]. BDI consists of 21 items 
referring to criteria of depression, e.g. anhedonia, 
lack of energy or diminished mood. Each item has 
four possible items, scored from 0 to 3. Psychiatric 
consultations were not performed.
The Patient Health Questionnaire 9 (PHQ-9) 
is another self-administered measure of depres-
sive symptoms. It was developed for the purposes 
of brief screening for mood disorders in clinical 
practice by Kroenke et al. [26]. Polish translation of 
PHQ-9 is available online [27]. The questionnaire 
consists of nine items, scored from 0 to 3, depending 
on the reported frequency of the symptoms. Higher 
scores indicate greater severity of the self-reported 
depressive symptoms in both BDI and PHQ-9.
The © FAS (Fatigue Assessment Scale: ILD 
care foundation (www.ildcare.nl) was used to 
assess the severity of fatigue in the studied sam-
ple. It was developed by de Vries et al. [17] and 
the Polish version (prepared by A. Dubaniewicz) 
is available online [28]. It comprises ten items 
divided into two five-item subscales: Physical 
Fatigue (FAS-P) and Mental Fatigue (FAS-M). 
Higher scores suggest greater severity of the ex-
perienced fatigue. 
Statistical analysis
Continuous variables were characterized by 
mean value (M) with respective standard devi-
ation (SD). Cronbach’s alpha for the SHQ were 
calculated to verify the reliability of the Polish 
version of the questionnaire. The validity of the 
SHQ was assessed by means of inter-group com-
parisons (active sarcoidosis vs PSFS vs control) 
and correlations with scores of other psychomet-
ric tools and the lung function test results. 
Analysis of variance was used for the in-
ter-group comparisons. The homogeneity of vari-
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Table 1.  Group characteristics and comparison of variables of interest between studied groups of patients with active 
sarcoidosis (AS), post-sarcoidosis fatigue syndrome (PSFS) and patients with sarcoidosis in remission without 
fatigue (S-R)
  Total (n = 71) S-R (n = 23) PSFS (n = 22) S-A (n = 26) p
Female (%) 34 (47.9%) 14 (60.9%) 7 (28.3%) 14 (53.8%) 0.059
Age 46.82 ± 12.3 43.78 ± 12.9 45.05 ± 12.44 51 ± 10.86 0.087
FEV1 88.83 ± 11.48 96.22 ± 8.62 86.95 ± 8.94† 83.88 ± 12.56†  < 0.001
FVC 91.92 ± 12.56 98.57 ± 12.86 91.05 ± 9.56 86.77 ± 12.27† 0.003
FEV1/FVC 0.77 ± 0.05 0.79 ± 0.04 0.77 ± 0.05 0.76 ± 0.06 0.077
DLCO 93.58 ± 12.35 96.87 ± 9.11 93.14 ± 9.95 91.04 ± 15.94 0.255
Radiological stage*
1/2/3/4
30/37/4/0 10/12/0/0 16/7/0/0 4/18/4/0
SHQ-PF 4.78 ± 1.1 5.78 ± 0.57 4.24 ± 1.04* 4.34 ± 0.9*  < 0.001
SHQ-EF 4.76 ± 0.99 5.86 ± 0.53 4.16 ± 0.59* 4.29 ± 0.74*  < 0.001
SHQ-DF 4.57 ± 1.07 5.75 ± 0.41 3.88 ± 0.75* 4.11 ± 0.81*  < 0.001
SHQ total 4.68 ± 0.97 5.79 ± 0.41 4.05 ± 0.57* 4.22 ± 0.73*  < 0.001
BDI 8.76 ± 6.07 3.74 ± 1.6 12.18 ± 6.93* 10.31 ± 4.95*  < 0.001
PHQ-9 5.37 ± 4.04 1.83 ± 1.23 7.95 ± 4.75* 6.31 ± 2.68*  < 0.001
FAS-P 12.17 ± 4.21 7.78 ± 1.35 15.82 ± 3.45*‡ 12.96 ± 2.81*  < 0.001
FAS-M 9.97 ± 2.96 7.09 ± 1.2 11.86 ± 2.83*‡ 10.92 ± 2.19*  < 0.001
FAS total 22.13 ± 6.76 14.83 ± 1.97 27.68 ± 5.45*‡ 23.88 ± 4.49*  < 0.001
Presented as mean values with standard deviations, with an exception for sex. SHQ — Sarcoidosis Health Questionnaire; PF — Physical Functioning; EF — Emotional 
Functioning; DF — Daily Functioning; BDI — Beck Depression Inventory; PHQ-9 — Patient Health Questionnaire; FAS — Fatigue Assessment Scale; FAS-P — Physical 
Fatigue; FAS-M — Mental Fatigue; FEV1 — forced expiratory volume in 1 second; FVC — forced vital capacity; DLCO — diffusing capacity or of the lung for carbon 
monoxide; p — probability in the test of significance; *p < 0.001 vs S-R; †p < 0.01 vs S-R; ‡p < 0.01 vs S-A
ance was checked with Levene’s test. The F test 
with post-hoc Tukey test were used if the variances 
between groups were assumed homogeneous. If 
the variance was assumed non-homogeneous, 
Welch test with post-hoc Dunnett T3 test was used. 
The association between two continuous variables 
was assessed with Pearson correlation quotients. 
The link between two continuous variables was 
assessed with Spearman correlation quotients in 
the subgroup analysis due to non-normal distribu-
tion of BDI and PHQ-9 (verified with Shapiro-Wilk 
test). The correlation coefficients were compared 
with an online tool [29]. Results were considered 
statistically significant when p < 0.05. SPSS 24.0 
(IBM, USA and Predictive Solutions, Poland) was 
used for all analyses.
Results
Clinical characteristics of study and control 
groups is presented in Table 1. The groups were 
not different it terms of age and gender. Patients 
with PSFS and active sarcoidosis had significan-
tly lower FEV1% predicted comparing to patients 
with complete remission and FVC% predicted 
was lower in active sarcoidosis comparing to 
PSFS group and complete remission group. 
Reliability of Polish adaptation of SHQ
Cronbach’s alpha for the SHQ was 0.95. Co-
efficient’s values for the DF, PF and EF domains 
were 0.91, 0.78 and 0.87, respectively. 
Validity of Polish adaptation of SHQ
Mean scores on PF, DF and EF scales and 
mean SHQ total score were higher among S-R 
patients than in PSFS patients and S-A patients 
(Fig. 1). Detailed results are shown in Table 1. 
Results of FAS, BDI and PHQ in all 3 groups of 
patients is shown in Figures 2–4.
There was a moderate, negative and statistical-
ly significant correlation between SHQ-PF and age (r 
= -0.308). SHQ-PF, EF, DF and total score correlated 
strongly, negatively and significantly with depres-
sive symptoms indicators, i.e. BDI (r = –0.660 to r 
= -0.804, p < 0.01) and PHQ-9 (r = –0.676 to r = 
–0,755, p < 0.01). A strong, negative and statistically 
significant correlations were also found between 
SHQ-PF, EF, DF and total score and chronic fatigue 
indicators, i.e. FAS total score (r = –0.711 to r = 
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Figure 1. Mean scores on Sarcoidosis Health Questionnaire (SHQ) scales 
compared between the studied groups of patients with active sarcoidosis 
(AS), post-sarcoidosis fatigue syndrome (PSFS) and patients with sarco-
idosis in remission without fatigue (S-R). PF — Physical Functioning (circ-
le); EF — Emotional Functioning (square); DF — Daily Functioning (trian-
gle). The bars represent the 95% Confidence Intervals for the mean values
Figure 4. Mean scores on Patient Health Questionnaire (PHQ-9) com-
pared between the studied groups of patients with active sarcoidosis 
(AS), post-sarcoidosis fatigue syndrome (PSFS) and patients with 
sarcoidosis in remission without fatigue (S-R). The bars represent the 
95% Confidence Intervals for the mean values
Figure 2. Mean scores on Fatigue Assessment Scale (FAS) scales 
compared between the studied groups of patients with active sar-
coidosis (AS), post-sarcoidosis fatigue syndrome (PSFS) and patients 
with sarcoidosis in remission without fatigue (S-R). FAS-P — Physical 
Fatigue (circle); FAS-M — Mental Fatigue (square). The bars represent 
the 95% Confidence Intervals for the mean values
Figure 3. Mean scores on Beck Depression Inventory (BDI) compared 
between the studied groups of patients with active sarcoidosis (AS), 
post-sarcoidosis fatigue syndrome (PSFS) and patients with sarcoid-
osis in remission without fatigue (S-R). The bars represent the 95% 
Confidence Intervals for the mean values
–0.784, p < 0.01) and its subscales, namely PA (r = 
–0.770 to r = –0.832, p < 0.01) and MA (r = –0.702 
to r = –0.779, p < 0.01). No statistically significant 
correlations were found between SHQ scores and 
lung function indicators (FEV1, FVC, FEV1/FVC or 
DLCO). Table 2 shows detailed results.
Correlates of the FAS score
Apart from the aforementioned correlations 
with SHQ scores, FAS total score correlated signi-
ficantly and positively with age, BDI score and 
PHQ-9 score. FAS Physical Fatigue scale score 
correlated with BDI score and PHQ-9, while FAS 
Mental Fatigue scale score was positively asso-
ciated with age and both BDI and PHQ-9 scores. 
Also, there was a weak, yet statistically significant 
and negative correlation between FAS-M score 
and FEV1. No other statistically significant corre-
lation was found between FAS scores and chosen 
lung function parameters (FEV1, FVC, FEV1/FVC 
or DLCO). Table 3 contains detailed results on the 
described correlation quotients.
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Table 3.  Pearson correlation coefficients of Fatigue  
Assessment Scale total score and its dimen-
sions scores with age and chosen indicators of 
depressive symptoms and lung capacity
  FAS total FAS-P FAS-M
Wiek 0.247* 0.212 0.266*
BDI 0.726** 0.670** 0.702**
PHQ-9 0.788** 0.768** 0.705**
FEV1 –0.221 –0.190 –0.235*
FVC –0.195 –0.184 –0.182
FEV1/FVC –0.168 –0.111 –0.226
DLCO –0.083 –0.056 –0.103
BDI — Beck Depression Inventory; PHQ-9 — Patient Health Questionnaire; FAS 
— Fatigue Assessment Scale; FAS-P — Physical Fatigue; FAS-M — Mental 
Fatigue; FEV1 — forced expiratory volume in 1 second; FVC — forced vital 
capacity; DLCO — diffusing capacity or of the lung for carbon monoxide; * p < 
0.05 (two-tailed); ** p < 0.01 (two-tailed)
Table 2.  Pearson correlation coefficients of Sarcoidosis Health Questionnaire total score and its dimensions scores with 
age and chosen indicators of depressive symptoms, chronic fatigue and lung capacity
  SHQ-PF SHQ-EF SHQ-DF SHQ total
Age –0.308* –0.146 –0.157 –0.200
BDI –0.660* –0.804* –0.715* –0.787*
PHQ–9 –0.690* –0.748* –0.676* –0.755*
FAS–P –0.778* –0.775* –0.770* –0.832*
FAS–M –0.743* –0.702* –0.732* –0.779*
FAS total –0.717* –0.764* –0.711* –0.784*
FEV1 0.150 0.194 0.155 0.180
FVC 0.209 0.151 0.104 0.153
FEV1/FVC 0.075 0.103 0.065 0.085
DLCO 0.089 0.091 0.111 0.107
PF — Physical Functioning; EF — Emotional Functioning; DF — Daily Functioning; BDI — Beck Depression Inventory; PHQ-9 — Patient Health Questionnaire; FAS — 
Fatigue Assessment Scale; FAS-P — Physical Fatigue; FAS-M — Mental Fatigue; FEV1 — forced expiratory volume in 1 second; FVC — forced vital capacity; DLCO 
— diffusing capacity of the lung for carbon monoxide; * p < 0.01 (two-tailed)
Subgroup analysis — FAS score vs 
depressive symptoms indicators
In the PSFS subgroup, there were positive 
and statistically significant correlations between 
the FAS dimensions and both BDI and PHQ-9 
scores (r = 0.448 to 0.693, p < 0.05), with an 
exception for the correlation between BDI and 
FAS-M (r = 0.407, p = 0.06). Similarly, in the 
S-A subgroup, FAS-M, FAS-P and FAS total score 
correlated positively and statistically significan-
tly with BDI and PHQ-9 (r = 0.456 to 0.748, p < 
0.05). There was an exception — the correlation 
between FAS-P and BDI was not found to be 
statistically significant (r = 0.356, p = 0.07). 
Despite no statistically significant difference of 
the aforementioned correlation quotients between 
the PSFS and control subgroups, three trends may 
be pointed out: the correlation quotient between 
PHQ-9 and FAS-P is higher in the PSFS group 
than in the S-A group (r = 0.673 vs r = 0.456, 
respectively, p = 0.30).
FAS-M correlates with BDI and PHQ-9 weaker 
in the PSFS group than in the S-A group (BDI: r 
= 0.407 vs 0.658, p = 0.25; PHQ-9: r = 0.464 vs 
0.749, p = 0.13).
The correlations between FAS dimensions 
and depressive symptoms indicators in the re-
mitted sarcoidosis group were found weak and 
statistically insignificant. Thus, it was assumed 
that the associations between those variables is 
either weaker than in the PSFS and active sarco-
idosis control subgroup or absent (Table 4). 
Discussion
This study was designed to validate Polish 
version of SHQ and to assess the relationship 
between health quality, depressive symptoms and 
fatigue. We also studied the level of health quality 
impairment and the intensity of depressive symp-
toms in patients with persistent chronic fatigue 
regardless clinical and radiological evidence of 
remission (post-sarcoidosis fatigue) and compa-
red it to control groups of patients with complete 
remission and active disease. Fatigue syndrome 
was defined by high total score of FAS equal to or 
higher than 22 points. In our study we positively 
validated the Polish version of SHQ. We also fo-
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Table 4.  Comparison of Spearman correlation coefficients of Fatigue Assessment scale total score and its dimensions 
scores with the chosen indicators of depressive symptoms between studied groups of patients with active 
sarcoidosis (AS), post-sarcoidosis fatigue syndrome (PSFS) and patients with sarcoidosis in remission without 
fatigue (S-R)
S-R (n = 23) PSFS (n = 22) S–A (n = 26)
  BDI PHQ-9 BDI PHQ-9 BDI PHQ-9
FAS-P –0.141 0.265 0.448* 0.673** 0.356 0.456*
FAS-M –0.132 0.075 0.407 0.464* 0.658** 0.749**
FAS total –0.131 0.227 0.486* 0.693** 0.607** 0.669**
BDI — Beck Depression Inventory; PHQ-9 — Patient Health Questionnaire; FAS — Fatigue Assessment Scale; FAS-P — Physical Fatigue; FAS-M — Mental Fatigue; 
* p < 0.05 (two-tailed); ** p < 0.01 (two-tailed)
und significantly impaired health quality in both 
post-sarcoidosis fatigue syndrome and active 
sarcoidosis patients. Depressive symptoms were 
significantly more frequent in PSFS, comparing 
to patients with complete remission, but were 
equally frequent as in active sarcoidosis group. 
Moreover, health quality was strongly related both 
to the presence of depressive symptoms as well 
as to intensity of fatigue. 
The Polish version of SHQ has reliability 
which is acceptable for the purposes of both 
clinical assessment and scientific research [30], 
Cronbach’s alpha for the SHQ and its dimensions 
is between 0.78 and 0.95. Those coefficients are 
slightly worse than those reported for the original 
SHQ [18], but comparable to the Japanese ada-
ptation [31]. The validity of the Polish version 
of the SHQ was verified by means of intergroup 
comparisons and calculation of correlation qu-
otients. It may be assumed that the adaptation is 
valid based on the following findings:
1. There was a negative correlation between 
SHQ scores and the depressive symptoms 
severity, i.e. the BDI and PHQ-9 scores. Sim-
ilar relationships between quality of life and 
depression has been previously reported for 
different diseases [32–34]. Depression and 
quality of life are both related to general 
well-being of the patient and emphasise the 
biopsychosocial aspects of the chronic dis-
ease. The association between them is proba-
bly two-way. Those terms may be considered 
as opposites since usually higher degree of 
depression is associated with low quality of 
life.
2.  There is a negative correlation between the 
SHQ scores and FAS scores. 
The SHQ scores were higher in PSFS and 
S-A groups than in the S-R group. No association 
between lung capacity indicators and SHQ score 
were found. Statistically significant correlations 
between FVC and FEV1 and SHQ score were repor-
ted in the original validation study [18] and only 
between FVC and SHQ in Japanese adaptation [31]. 
However, it should be noted that the correlation 
coefficients were low, which suggests a  small 
effect size. Thus, this results might be replicated 
in a sample larger than hereby research. The low 
number of patients with severe sarcoidosis, with 
severely impaired lung function may be also re-
sponsible for the lack of such correlation. 
In our work we focused mainly on post-sar-
coidosis fatigue syndrome, and the study was not 
aimed to solve the problem of fatigue etiopathoge-
nesis. We can only resume, that fatigue in general 
influences the health quality and is related to 
depressive symptoms. Health quality was equally 
impaired in PSFS and active sarcoidosis. There was 
only a non-significant trend towards higher scores 
in DPI and PHQ-9 questionnaires in PSFS compa-
ring to active sarcoidosis, suggesting the influence 
of active chronic disease on these symptoms. FAS 
was positively correlated with depressive symp-
toms, and this correlation was especially strong in 
a subgroup analysis of PSFS patients. 
We found only weak negative correlation 
between FAS mental fatigue score and FEV1. 
Baydur et al found a negative correlation between 
vital capacity (VC) and mental fatigue assessed 
by another fatigue questionnaire, a 20-item mul-
tidimentional fatigue inventory (MFI-20) [35]. 
Another group of Polish authors have not found 
correlations between fatigue severity assessed 
by FAS and lung function test parameters (spi-
rometry and DLCO) [36]. As already mentioned 
above, our study groups were not represented by 
patients with the most severe disease, therefore 
it is difficult to conclude on the importance of 
impaired lung function on fatigue based on our 
results. In our opinion, in the multidimensional 
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aspect of fatigue etiopathogenesis impaired lung 
function should still be considered as a potential 
cause of fatigue.
In previous studies FAS was proved an ex-
cellent unidimensional tool for the assessment 
of multidimensional syndrome [8, 17]. Although 
fatigue in sarcoidosis should be considered as 
a syndrome of many possible causes and com-
plicated background (multidimensionality) [10], 
FAS measures fatigue independently of depressive 
symptoms (it is unidimensional) [17]. Never-
theless, both anxiety and depressive symptoms 
were shown to be significant predictors of high 
fatigue scores [16]. In our study we confirmed 
this links, also in this particular situation, when 
fatigue persists in patients with radiological and 
clinical remission. 
De Kleijn et al. [37], based on the anchor-ba-
sed and distribution-based methods, estimated 
a 4-point difference in the FAS scores to be the 
minimal clinically important differences (MCID). 
Although the purpose of the cited study was to 
find the clinically important difference for longi-
tudinal assessments, it is of note, that in our stu-
dy mean FAS values between S-R and S-A/PSFS 
groups were much above this threshold. Also the 
difference between S-A and PSFS, although not 
clinically significant, was higher in PSFS group 
and equalled the MCID value. 
In summary, Polish version of SHQ is a valid 
instrument for the assessment of health quality. 
Health quality is impaired in post-sarcoidosis 
fatigue syndrome, when compared to patients 
with complete remission, and the level of this im-
pairment is comparable to that observed in active 
sarcoidosis. Health quality is strongly related to 
depressive symptoms and fatigue. The intensity 
of depressive symptoms is higher in PSFS com-
paring to complete remission, but comparable to 
active disease.
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